GNTA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 10:59):

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy...

Stats
Today's Volume	5 333.00
Average Volume	5 524.00
Market Cap	49.00M
EPS	$0 ( 2024-04-24 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.96
ATR14	$0.0710 (2.49%)

Insider Trading

Date	Person	Action	Amount	type
2008-10-06	Driscoll Martin J	Buy	4 999	Options to acquire Common Stock
2008-04-11	Sanders Walter Lloyd	Buy	65 000	Restricted Stock Unit
2007-01-03	Sanders Walter Lloyd	Sell	53	Common Stock, par value $.001
2007-01-03	Sanders Walter Lloyd	Sell	51	Common stock, par value $.001
2007-07-11	Driscoll Martin J	Buy	30 000	Options to acquire Common Stock

INSIDER POWER
0.00
Last 60 transactions
Buy: 9 070 639 \| Sell: 19 095 969

Volume Correlation

Long: 0.09 (neutral)

Short: 0.02 (neutral)

Signal:(61.587) Neutral

Genenta Science S.p.A. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Genenta Science S.p.A. Correlation - Currency/Commodity

0.28
( neutral )

0.70
( moderate )

0.00
( neutral )

0.56
( weak )

-0.27
( neutral )

-0.32
( neutral )

Genenta Science S.p.A. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-41 582.00 (0.00 %)
EPS:	$-0.630

Q4	2023
Revenue:	$0
Gross Profit:	$-20 883.00 (0.00 %)
EPS:	$-0.260

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.130

Q2	2023
Revenue:	$0
Gross Profit:	$-20 946.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Genenta Science S.p.A.

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.